Dnaprint Genomics Inc – ‘8-K’ for 5/8/06

On:  Friday, 5/12/06, at 4:30pm ET   ·   For:  5/8/06   ·   Accession #:  1231742-6-346   ·   File #:  0-31905

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         2     11K 
 2: EX-10.43    Material Contract                                     32±   108K 

8-K   —   Current Report
Document Table of Contents

8-K
1st Page of 2
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON  D. C.  20549

FORM 8-K

   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE
ACT OF 1934.

 MAY 8, 2006
Date of Report (Date of Earliest Event Reported)

 DNAPRINT GENOMICS, INC.
(Exact name of Registrant as specified in charter)

 COMMISSION FILE NUMBER: 0-31905

   UTAH                                                   59-2780520
(State  of Incorporation)                              (I.R.S. Employer I.D. No)

 900 COCOANUT AVENUE, SARASOTA, FL 34236
(Address of Principal Executive Offices)

(941) 366-3400
(Registrant's Telephone Number, Including Area Code)

     Check  the  appropriate  box  below  if  the Form 8-K filing is intended to
simultaneously  satisfy the filing obligation of the registrant under any of the
following  provisions  (see  General  Instruction  A.2.  below):                

[ ]     Written communications pursuant to Rule 425 under the Securities Act (17
CFR  230.425)                                                   

[ ]     Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 
CFR  240.14a-12)                                                

[ ]     Pre-commencement  communications  pursuant  to  Rule 14d-2(b) under the 
Exchange  Act  (17  CFR  240.14d-2(b))                          

[ ]     Pre-commencement  communications  pursuant  to  Rule 13e-4(c) under the 
Exchange  Act  (17  CFR  240.13e-4(c))                          

8-K
Last Page of 2
TOC
1st
Previous
Next
↓Bottom
Just 2nd
 2
ITEM  1.01     ENTRY  INTO  A  MATERIAL  DEFINITIVE  AGREEMENT                  

GMP  Manufacturing  Services  Agreement  with  KBI  BioPharma,  Inc.            
--------------------------------------------------------------------            

     Effective  May  8,  2006,  the Registrant entered into a Services Agreement
(the "Agreement") with KBI BioPharma, Inc., a Delaware company ("KBI"). KBI is a
process development and manufacturing service provider for the biopharmaceutical
industry.  Under  the  terms  of  the  Agreement,  KBI  will manufacture for the
Registrant  PT-401,  a  more  powerful  form  of  the anemia drug Erythropoietin
("EPO"). EPO is a glycoprotein naturally made by the body to stimulate red blood
cell production; the currently marketed forms are manufactured using recombinant
DNA  technology  and  are  used  to  treat  anemia  or  low  blood  cell  count.

     As  previously  announced  on  April 4, 2005, the Registrant entered into a
License  Agreement  with  Beth  Israel Deaconess Medical Center, a Massachusetts
nonprofit  corporation,  to develop a new, more potent and longer acting form of
EPO.  Under  the  Agreement, Beth Israel has granted the Registrant an exclusive
license  to  United  States and foreign patents related to certain forms of EPO,
including  PT-401. The Registrant has the right to develop, use, market and sell
products  derived  from  the  licensed  patents.                                

     Under  the  Agreement,  KBI will develop and manufacture material under the
Good Manufacturing Practices rules for use in preclinical studies required for a
future  Investigational  New  Drug application, including toxicology studies and
studies  involving volunteers and patients. The cost of the services provided by
KBI  under the Agreement totals approximately $2,840,000 and will be invoiced by
KBI  semi-monthly  for  work  in  process  based upon an agreed scope of work, a
Development  and Production Schedule and a Payment Schedule contained within the
Agreement. The estimated time for completion of the project is 16-24 months, and
work  is  scheduled  to  begin  in  May,  2006.                                 

     ITEM  2.03     CREATION  OF  A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION
UNDER  AN  OFF-BALANCE  SHEET  ARRANGEMENT  OF  A  REGISTRANT.                  

See  Item  1.01  above.                                               

ITEM  9.01     FINANCIAL  STATEMENTS  AND  EXHIBITS                   

          (d)     Exhibit  10.43 - Services Agreement between the Registrant and
KBI  BioPharma,  Inc.  dated  May  8,  2006.                                    

SIGNATURES

     Pursuant  to  the  requirements of the Securities Exchange Act of 1934, the
Registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned,  thereunto  duly  authorized.                                      

DNAPrint  Genomics,  Inc.                                             

By:  /s/Richard  Gabriel                                              
-------------------                                         
Richard  Gabriel,  President                                        

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
Filed on:		5/12/06
For Period End:		5/8/06		1		2
		4/4/05		2					8-K,  8-K/A
									List all Filings